Literature DB >> 12735506

The physical burden of prostate cancer.

David F Penson1, Mark S Litwin.   

Abstract

The physical burden of prostate cancer is considerable and affects quality of life in men with both localized and metastatic disease. This physical impact results as much from treatment for prostate cancer as from the disease itself. In advanced disease, although patients can experience considerable pain and discomfort from bony lesions, they also can experience bothersome fatigue and sleep disturbances from institution of hormone ablation therapy. In localized disease, although patients can have lower urinary tract symptoms from untreated prostate cancer, all aggressive treatments can result in urinary, sexual, and bowel dysfunction that can bother the patient and affect quality of life. Patients and providers must be vigilantly aware of the physical burden of prostate cancer when initiating treatment for this disease and during follow up after treatment. By being cognizant of the physical impact of prostate cancer on quality of life, providers can address patients' problems early in their course of treatment and maximize patients' HRQOL and overall satisfaction with care.

Entities:  

Mesh:

Year:  2003        PMID: 12735506     DOI: 10.1016/s0094-0143(02)00187-8

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  7 in total

1.  Early hormonal therapy for prostate cancer: the good, the bad, and the ugly.

Authors:  Stephen J Freedland; Alan W Partin
Journal:  Rev Urol       Date:  2005

Review 2.  Active surveillance and radical therapy in prostate cancer: can focal therapy offer the middle way?

Authors:  Hashim Uddin Ahmed; Mark Emberton
Journal:  World J Urol       Date:  2008-08-14       Impact factor: 4.226

Review 3.  Early versus delayed hormonal treatment in locally advanced or asymptomatic metastatic prostatic cancer patient dilemma.

Authors:  Domenico Prezioso; Fabrizio Iacono; Giuseppe Romeo; Antonio Ruffo; Nicola Russo; Ester Illiano
Journal:  World J Urol       Date:  2013-08-08       Impact factor: 4.226

Review 4.  Impact of abiraterone on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives.

Authors:  Joelle El-Amm; Rami Nassabein; Jeanny B Aragon-Ching
Journal:  Cancer Manag Res       Date:  2017-07-11       Impact factor: 3.989

5.  Prostate Cancer Drug Therapy: What Have Clinicians Missed During the COVID-19 Pandemic.

Authors:  M S Rahnama'i
Journal:  Am J Mens Health       Date:  2022 Jul-Aug

6.  Olaparib outcomes in metastatic castration-resistant prostate cancer: First real-world experience in safety and efficacy from the Chinese mainland.

Authors:  Jian Pan; Dingwei Ye; Yao Zhu
Journal:  Prostate Int       Date:  2022-05-06

7.  Cholesterol biosynthesis inhibitor RO 48-8071 suppresses growth of hormone-dependent and castration-resistant prostate cancer cells.

Authors:  Yayun Liang; Benford Mafuvadze; Johannes D Aebi; Salman M Hyder
Journal:  Onco Targets Ther       Date:  2016-05-30       Impact factor: 4.147

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.